Drug intelligence / Profile preview

EPA + DHA phospholipids

Development stage
Preclinical
Lead developer
Aker BioMarine
Modality
Small Molecules
Administration
Oral
01

Overview

EPA + DHA phospholipids is a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) esterified to a phospholipid backbone, rather than as triglycerides or ethyl esters. This form is found naturally in certain marine sources such as krill oil. Phospholipid-bound EPA and DHA are critical components of cell membranes, especially in the brain and retina, where they influence membrane fluidity, lipid raft formation, signal transduction pathways, and cellular function[5][9]. The mechanism of action includes anti-inflammatory effects through modulation of eicosanoid production (such as resolvins), reduction of plasma triglyceride levels by acting as poor substrates for enzymes involved in triglyceride synthesis, inhibition of platelet aggregation, prolongation of bleeding time, reduction in plasma fibrinogen levels[6][3], and support for cardiovascular health. Phospholipid forms may have superior bioavailability for brain uptake compared to other forms[7][9]. Primary indications include dietary supplementation for cardiovascular risk reduction (notably hypertriglyceridemia), cognitive support/brain health (including potential roles in dementia/Alzheimer’s disease), mood disorders such as depression or ADHD support[1][8][9], with ongoing research into additional benefits.

Brand names
Omega-3 PhospholipidsOmega3 PhospholipidsOmega 3 Phospholipids
Other names
omega-3 phospholipidsomega3 phospholipidsomega 3 phospholipidskrill oilPL-EPA + PL-DHA

Beyond the preview

Go deeper on EPA + DHA phospholipids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPA + DHA phospholipids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call